TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06122753

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: preemptive TIPS
Description: The TIPS procedure should be performed within 72 hours after the initial endoscopic examination or treatment. An 8 mm Viatorr stent will be used for TIPS establishment. The aim will be to reduce the portal pressure gradient below 12 mm Hg. Embolization, either with coils or glue, can be performed, if it is felt necessary, especially in patients where portography shows the filling of large portosystemic collaterals feeding the varices. After TIPS, anticoagulation will not be used as a rule but is allowed if the attending physician thinks that it is warranted.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard second prophylaxis
Description: Patients will receive vasoactive drugs up to 5 days; then a non-selective beta-blocker (carvedilol) will be started with an initial dose of 6.25 mg, the dose of propranolol will be increased to 12.5 mg.~The second elective session of endoscopic band ligation will be performed within the first 28 days after the initial endoscopic treatment. The following sessions will be performed at 28 +/- 3 days intervals until variceal eradication. Once eradication is achieved, endoscopic monitoring will be performed every 6 months. If varices reappear, new band ligation will be performed.
Study: NCT06065904

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrilect
Description: This intervention involves a comprehensive approach that includes a thorough nutritional assessment and individualized nutrition plan for children with cerebral palsy (CP) and Autism Spectrum Disorder (ASD), addressing their unique dietary needs and challenges. It encompasses nutritional counseling, dietary modifications when necessary, and seamless integration with other therapies, including speech therapy and psychological consultation. The overarching goal is to optimize growth, muscle function, and overall well-being in these children by providing tailored nutritional support alongside a holistic care approach.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrilect
Description: This intervention involves a comprehensive approach that includes a thorough nutritional assessment and individualized nutrition plan for children with cerebral palsy (CP) and Autism Spectrum Disorder (ASD), addressing their unique dietary needs and challenges. It encompasses nutritional counseling, dietary modifications when necessary, and seamless integration with other therapies, including speech therapy and psychological consultation. The overarching goal is to optimize growth, muscle function, and overall well-being in these children by providing tailored nutritional support alongside a holistic care approach.
Study: NCT04259983

Intervention type: OTHER
Intervention: Endothelial dysfunction assessment
Description: Endothelial dysfunction will be determined by blood samples. Blood samples will be collected and analyzed for the responses of ICAM-1, VCAM-1, E-Selectin, VEGF, ET-1.

Intervention type: OTHER
Intervention: Endothelial dysfunction assessment
Description: Endothelial dysfunction will be determined by blood samples. Blood samples will be collected and analyzed for the responses of ICAM-1, VCAM-1, E-Selectin, VEGF, ET-1.

Intervention type: OTHER
Intervention: Arterial stiffness assessment
Description: Arterial stiffness, oscillometric pulse wave velocity (PWV) and augmentation index will be evaluated by recorded brachial pulse waves with automatically with the oscillometric device.

Intervention type: OTHER
Intervention: Arterial stiffness assessment
Description: Arterial stiffness, oscillometric pulse wave velocity (PWV) and augmentation index will be evaluated by recorded brachial pulse waves with automatically with the oscillometric device.

Intervention type: OTHER
Intervention: Arterial stiffness assessment
Description: Arterial stiffness, oscillometric pulse wave velocity (PWV) and augmentation index will be evaluated by recorded brachial pulse waves with automatically with the oscillometric device.
Study: NCT04594707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRM-151 (Zinpentraxin Alfa)
Description: Cohort A: Participants will receive three loading doses of open-label PRM-151 on days 1, 3, and 5, then one infusion every 4 weeks (Q4W). 10 mg/kg of PRM 151 will be administered by intravenous (IV) infusion over 60 minutes on days 1, 3, and 5, then one infusion every 4 weeks.~Cohort B: Participants previously randomized to the placebo in WA42293 will receive study medication in the three loading doses on days 1, 3 and 5 in a blinded fashion. All three doses will contain PRM-151. Participants previously randomized to the treatment arm in WA42293 will receive study medication in the three loading doses on days 1, 3 and 5 in a blinded fashion. One of the three doses will contain PRM-151, whereas two doses will contain placebo.
Study: NCT05042375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: camrelizumab + famitinib
Description: Camrelizumab for injection, 200 mg; Famitinib malate capsules, 20 mg.
Study: NCT06348706

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dipeptidyl peptidase 4 (DPP-4) inhibitor
Description: Intervention group received Dipeptidyl peptidase-4 (DPP-4) inhibitors supplementation in a dose of 50 mg with main meal for 6 months.
Study: NCT05944120

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Aromatherapy patches
Description: This study anticipates that Staff-reported stress levels will decrease when nurses use strategies from the Crisis Intervention Cart while at work.
Study: NCT04241666

Intervention type: DIAGNOSTIC_TEST
Intervention: renal scintigraphy
Description: Technetium-99m-dimercaptosuccinic acid scintigraphy of both kidneys

Intervention type: DIAGNOSTIC_TEST
Intervention: renal scintigraphy
Description: Technetium-99m-dimercaptosuccinic acid scintigraphy of both kidneys

Intervention type: DIAGNOSTIC_TEST
Intervention: renal scintigraphy
Description: Technetium-99m-dimercaptosuccinic acid scintigraphy of both kidneys

Intervention type: DIAGNOSTIC_TEST
Intervention: renal doppler sonography
Description: doppler ultrasound of both kidneys

Intervention type: DIAGNOSTIC_TEST
Intervention: renal doppler sonography
Description: doppler ultrasound of both kidneys

Intervention type: DIAGNOSTIC_TEST
Intervention: renal doppler sonography
Description: doppler ultrasound of both kidneys
Study: NCT06633211

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alveolar ridge preservation using DBBM + Regenfast + collagen matrix
Description: Post extraction sites be filled up to the level of the highest point of the alveolar bone crest using particulate DBBM xenograft (Bio-Oss, Geistlich Pharma AG, Wolhusen, Switzerland) mixed with polynucleotide and hyaluronic acid-based gel (Regenfast®). The alveolus will be sealed with a porcine collagen membrane (Mucograft Seal, Geistlich Pharma AG, Wolhusen, Switzerland) and secured with 4-6 simple interrupted sutures (Resolon 6-0, Resorba Medical GmbH, Nuremberg, Germany).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Alveolar ridge preservation using DBBM + collagen matrix
Description: Post extraction sites be filled up to the level of the highest point of the alveolar bone crest using particulate DBBM xenograft (Bio-Oss, Geistlich Pharma AG, Wolhusen, Switzerland). The alveolus will be sealed with a porcine collagen membrane (Mucograft Seal, Geistlich Pharma AG, Wolhusen, Switzerland) and secured with 4-6 simple interrupted sutures (Resolon 6-0, Resorba Medical GmbH, Nuremberg, Germany).
Study: NCT05460572

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Peripheral Parental Nutrition
Description: Peripheral parenteral nutrition (PPN) through an intravenous (iv) line
Study: NCT04619719

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Therapy (HBOT)
Description: Patients assigned to the treatment arm will receive up to 5 treatments of hyperbaric oxygen therapy administered daily at 2.0 atmospheres for 90 minutes per session.
Study: NCT05023382

Intervention type: DRUG
Intervention: Teduglutide
Description: Teduglutide 0.05 mg/kg SC injection
Study: NCT06532253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVDX3
Description: NVDX3 is implanted during a single surgical intervention, that took place in the core trials (refer to NCT05961956 and NCT05987033)
Study: NCT06248541

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: treatment with low-level laser therapy
Description: low-level laser therapy (wavelength of 620 - 640nm)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: treatment with conventional light diodes
Description: conventional light diodes
Study: NCT04738474

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promoting Resilience in Stress Management (PRISM)
Description: Develops personal resilience resources through 1:1 sessions with a PRISM coach.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: No additional study-specific interaction with subjects. Subjects continue to receive usual medical care.
Study: NCT05042375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: pembrolizumab 200 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: camrelizumab
Description: Camrelizumab for injection, 200 mg.
Study: NCT05507645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Prourokinase for Injection (rhPro-UK)
Description: 15mg of rhPro-UK intravenous bolus within 3 minutes, and the remaining 20mg intravenous drip within 30 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard medical treatment
Description: Standard antiplatelet or anticoagulant treatment at the discretion of local investigators.
Study: NCT06445634

Intervention type: OTHER
Group type: OTHER
Intervention: Gonioscopy-Assisted Transluminal Trabeculotomy Combined with Goniosynechiolysis
Description: Gonioscopy-Assisted Transluminal Trabeculotomy Combined with Goniosynechiolysis in Glaucoma Patients with Secondary Synechial Angle Closure
Study: NCT05267535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piromelatine 20 mg
Description: Tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets
Study: NCT05792163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNP318 (A)
Description: Capsule for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (B)
Description: Placebo capsules matching the SNP318 capsules
Study: NCT06386211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAGNE-B6 Oral Solution
Description: Oral solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAGNE-B6 Oral Solution
Description: Oral solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAGNE-B6 New Formulation Tablet
Description: New formulation tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAGNE-B6 New Formulation Tablet
Description: New formulation tablet.
Study: NCT04882631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI-100 Topical Cream
Description: A dose of approximately 560 ug (approximately 0.4 mL of each of the three concentrations to 3 different sites) of PBI-100 was applied daily (excluding weekends) to the skin test sites.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Positive Control - Sodium laurel sulfate (SLS)
Description: Approximately 0.4 mL of 0.25% SLS was applied daily (excluding weekends) as a positive control test site.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PBI-100 Topical Cream, Vehicle
Description: Approximately 0.4 mL of 0% placebo cream was applied daily (excluding weekends) as a positive control test site.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Negative Control
Description: A blank patch was applied daily (excluding weekends) as a negative control test site.
Study: NCT06049836

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Holograms
Description: Clinical decision making based on visualising liver 3D holographic augmented reality liver models

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Holograms
Description: Clinical decision making based on visualising liver 3D holographic augmented reality liver models

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PDF
Description: Clinical decision making based on visualisation of 3D liver rendering on computer monitors on a PDF file

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PDF
Description: Clinical decision making based on visualisation of 3D liver rendering on computer monitors on a PDF file
Study: NCT04406597

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the New Tissue Containment System
Description: Laparoscopic Ovarian Cystectomy using the New Tissue Containment System
Study: NCT04682730

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deliberative Loop
Description: The investigators will give background information to the stakeholders before they engage in the Deliberative session.~Stakeholders from a given clinic will come together for a Deliberative session (i.e., facilitated conversation), enabling them to hear the full range of perspectives held by their fellow colleagues and to share their own perspective regarding how best to implement the guideline in small-group discussions.~Following the Deliberative session, each stakeholder will have the opportunity to record their opinions regarding possible implementation interventions. The investigators will share these opinions with the clinic's decision-makers to help guide their decision-making about which implementation interventions to deploy. If a stakeholder happens to be absent the day of their clinic's Deliberative session, they will still have the opportunity to complete the survey.
Study: NCT05960318

Intervention type: DEVICE
Intervention: KalobaNaso spray
Description: Nasal spray, 2 puff per nostril, 3 times a day

Intervention type: DEVICE
Intervention: KalobaNaso junior spray
Description: Nasal spray, 1 puff per nostril, 3 times a day
Study: NCT05243979

Intervention type: RADIATION
Intervention: DEXA scan
Description: bone study
Study: NCT06308601

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laughter yoga
Description: Laughter is an innate, most natural, sincere and universal response to humorous stimuli. Philosophically, it is explained by relief theory, conflict theory and superiority theory (Öztürk \& Tezel, 2021). The emergence of laughter yoga was made by Dr., an Indian medical doctor, in 1995. It was created by combining breathing exercises and unconditional laughter with the work of Madan Kataria and his wife Madhuri Kataria. In laughter yoga, the individual can laugh in a simulated way with the interaction of group members, without a funny situation, joke or joke. The body cannot distinguish between real and unreal laughter, and fake laughter begins to turn into real laughter (Kataria, 2011).
Study: NCT05750108

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Parasym device (active, current (mA) < discomfort threshold)
Description: Active transcutaneous Vagal Nerve Stimulation (tVNS) (Parasym device, Parasym Health, Inc, London, UK) will be performed with a clip attached to the ear at 20 hertz (Hz), 250 microseconds (ms) at a current just below discomfort threshold for 30 minutes twice a day, starting on post-MI day 0. Stimulation will continue until 7 days post-MI or discharge.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Parasym device (sham, current (mA) = 0)
Description: Parasym device will be attached to the ear twice a day, turned on but current set to 0 milliamp (mA), starting on post-MI day 0. Stimulation will continue until 7 days post-MI or discharge.
Study: NCT05474456

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SNAGs
Description: Wrestlers will be treated with high velocity, low amplitude thrust. The treatment will be given for 6 weeks, 2 sessions per week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manipulation
Description: Wrestlers will be treated with high velocity, low amplitude thrust. The treatment will be given for 6 weeks, 2 sessions per week.
Study: NCT05832099

Intervention type: RADIATION
Intervention: Radiation
Description: The techniques of conformal focal-brain irradiation in the era of modern radiotherapy (i.e., conventionally fractionated VMAT, hypofractionated stereotactic radiotherapy, and proton beam therapy, etc)
Study: NCT04906083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avatrombopag
Description: Avatrombopag:~PLT：30\~50×10\^9/L patients, 40 mg/d; PLT：\<30×10\^9/L patients, 60 mg/d.

Intervention type: DRUG
Group type: OTHER
Intervention: Standard medical treatment
Description: Standard medical treatment included transmetil, compound glycyrrhizinate, reduced glutathione and hepatocyte growth factor, et. al.
Study: NCT04796129

Intervention type: OTHER
Intervention: the patients with hip osteoarthritis and their inflammatory status
Description: The participants in the experimental group will be evaluated for the hip osteoarthritis. They will take and X-ray for hip joints and also hemogram for the excluding the inflammatory diseases.

Intervention type: OTHER
Intervention: the patients with hip osteoarthritis and their inflammatory status
Description: The participants in the experimental group will be evaluated for the hip osteoarthritis. They will take and X-ray for hip joints and also hemogram for the excluding the inflammatory diseases.
Study: NCT04306458

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimally invasive esophagectomy
Description: Conventional minimally invasive esophagectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally invasive esophagectomy
Description: Conventional minimally invasive esophagectomy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: daVinci Xi system
Description: robot assisted minimally invasive esophagectomy
Study: NCT06460038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenapanor
Description: Inhibitor of NH3

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drug
Study: NCT05707338

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastrectomy with lymph node dissection
Description: prospective randomized comparative clinical trial study analyzing outcomes of gastrectomy for early gastric cancer using laporoscopy versus open approach. This will be a prospective comparative study at Sohag University Hospital, Egypt and National Cancer Institute(NCI), Cairo university ,Egypt.~Patients were divided randomizly into two groups; the first group included patients who will have laparoscopic gastrectomy (Lap group), and the second group included patients will receive open gastrectomy (Open group).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastrectomy with lymph node dissection
Description: prospective randomized comparative clinical trial study analyzing outcomes of gastrectomy for early gastric cancer using laporoscopy versus open approach. This will be a prospective comparative study at Sohag University Hospital, Egypt and National Cancer Institute(NCI), Cairo university ,Egypt.~Patients were divided randomizly into two groups; the first group included patients who will have laparoscopic gastrectomy (Lap group), and the second group included patients will receive open gastrectomy (Open group).
Study: NCT05326607

Intervention type: DEVICE
Group type: OTHER
Intervention: Prototype of adaptive eyeglasses
Description: The tested investigational medical device is a prototype of semi-integrated eyeglasses.

Intervention type: DEVICE
Group type: OTHER
Intervention: Prototype of adaptive eyeglasses
Description: The tested investigational medical device is a prototype of semi-integrated eyeglasses.

Intervention type: DEVICE
Group type: OTHER
Intervention: Comparator
Description: The comparator is either a pair of progressive lenses that provide clear vision at both distance and near vision, either, for wearers who have rejected progressive glasses, an alternative solution providing clear vision at both distance and near vision which can consist of bifocal glasses, multifocal or monovision lenses, multiple pairs of glasses or one pair for cases of emmetropia.

Intervention type: DEVICE
Group type: OTHER
Intervention: Comparator
Description: The comparator is either a pair of progressive lenses that provide clear vision at both distance and near vision, either, for wearers who have rejected progressive glasses, an alternative solution providing clear vision at both distance and near vision which can consist of bifocal glasses, multifocal or monovision lenses, multiple pairs of glasses or one pair for cases of emmetropia.
Study: NCT04906083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard medical treatment
Description: Standard medical treatment included transmetil, compound glycyrrhizinate, reduced glutathione and hepatocyte growth factor, et. al.
Study: NCT05778552

Intervention type: DEVICE
Intervention: Home-based pelvic muscle training devices or traditional PFMT at hospital
Description: Performed home-based pelvic muscle training devices at home or traditional PFMT at hospital

Intervention type: DEVICE
Intervention: Home-based pelvic muscle training devices or traditional PFMT at hospital
Description: Performed home-based pelvic muscle training devices at home or traditional PFMT at hospital
Study: NCT04551430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib will be supplied by Exelixis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib will be supplied by Exelixis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib will be supplied by Exelixis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be provided free of charge (as investigational supply) by Bristol-Myers Squibb.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be provided free of charge (as investigational supply) by Bristol-Myers Squibb.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab will be provided free of charge (as investigational supply) by Bristol-Myers Squibb.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab will be provided free of charge (as investigational supply) by Bristol-Myers Squibb.